BRPI0908050A2 - Furo-e tieno[3,2-c]piridinas - Google Patents

Furo-e tieno[3,2-c]piridinas

Info

Publication number
BRPI0908050A2
BRPI0908050A2 BRPI0908050-3A BRPI0908050A BRPI0908050A2 BR PI0908050 A2 BRPI0908050 A2 BR PI0908050A2 BR PI0908050 A BRPI0908050 A BR PI0908050A BR PI0908050 A2 BRPI0908050 A2 BR PI0908050A2
Authority
BR
Brazil
Prior art keywords
furo
thieno
pyridines
Prior art date
Application number
BRPI0908050-3A
Other languages
English (en)
Inventor
Mark J Mulvihill
Jing Wang
Xin Chen
Ti Wang
An-Hu Li
Arno G Steinig
Andrew Kleinberg
Qinghua Weng
Hanqing Dong
Meizhong Jin
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0908050A2 publication Critical patent/BRPI0908050A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0908050-3A 2008-02-06 2009-02-06 Furo-e tieno[3,2-c]piridinas BRPI0908050A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6380008P 2008-02-06 2008-02-06
US11955308P 2008-12-03 2008-12-03
PCT/US2009/033311 WO2009100282A1 (en) 2008-02-06 2009-02-06 Furo-and thieno[3,2-c] pyridines

Publications (1)

Publication Number Publication Date
BRPI0908050A2 true BRPI0908050A2 (pt) 2015-08-11

Family

ID=40524808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908050-3A BRPI0908050A2 (pt) 2008-02-06 2009-02-06 Furo-e tieno[3,2-c]piridinas

Country Status (19)

Country Link
US (1) US8022206B2 (pt)
EP (1) EP2265616B8 (pt)
JP (1) JP2011511094A (pt)
KR (1) KR20110014971A (pt)
CN (1) CN102007127A (pt)
AR (1) AR070317A1 (pt)
AU (1) AU2009212338A1 (pt)
BR (1) BRPI0908050A2 (pt)
CA (1) CA2711078A1 (pt)
CL (1) CL2009000275A1 (pt)
EA (1) EA201070929A1 (pt)
ES (1) ES2451024T3 (pt)
IL (1) IL206758A0 (pt)
MX (1) MX2010008638A (pt)
PE (1) PE20091414A1 (pt)
TW (1) TW200944201A (pt)
UY (1) UY31638A1 (pt)
WO (1) WO2009100282A1 (pt)
ZA (1) ZA201005554B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2780922A1 (en) * 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
WO2011109593A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Substituted-5-aminopyrrolo/pyrazolopyridines
CA2796967C (en) * 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
US10614666B2 (en) 2011-04-20 2020-04-07 Video Gaming Technologies, Inc. Gaming machines with free play bonus mode presenting only winning outcomes
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
CN104364257B (zh) * 2012-03-23 2017-03-01 纪念斯隆-凯特琳癌症中心 5‑酰基‑6,7‑二氢噻吩并[3,2‑c]吡啶类化合物对胰腺及相关癌症的治疗作用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR101582852B1 (ko) 2012-05-24 2016-01-07 서울대학교 산학협력단 타우 단백질 매개 신경 퇴행성 질환 치료제
EP3483167A1 (en) 2013-06-26 2019-05-15 AbbVie Inc. Primary carboxamides as btk inhibitors
US9907791B2 (en) * 2014-03-14 2018-03-06 University Of Utah Research Foundation Ron inhibitors for use in preventing and treating bone loss
CN103923081B (zh) * 2014-04-14 2017-06-27 武汉光谷人福生物医药有限公司 化合物及其制备方法和应用
EP3229836B1 (en) 2014-12-09 2019-11-13 Institut National de la Sante et de la Recherche Medicale (INSERM) Human monoclonal antibodies against axl
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
CN106866447A (zh) * 2017-03-30 2017-06-20 成都绿林科技有限公司 一种合成对乙酰基苯甲酰胺的方法
US10957159B2 (en) 2018-04-12 2021-03-23 Aristocrat Technologies Australia Pty Limited Gaming machine and method for displaying a free spin count-up
US11427596B2 (en) * 2019-07-19 2022-08-30 Indian Institute of Technology Indore Metal-free solvent-free synthesis of fused-pyrido heterocycles and biomedical applications
UY39890A (es) * 2021-08-10 2023-03-31 Jacobio Pharmaceuticals Co Ltd Compuestos con diana en mutante de p53
KR20250079173A (ko) 2022-10-03 2025-06-04 고리츠다이가쿠호진 요코하마시리츠다이가쿠 이환성 구조를 갖는 이미다조피리딘 유도체
EP4635954A1 (en) * 2022-12-15 2025-10-22 Iregene Therapeutics Co., Ltd Inducer for inducing mesenchymal-epithelial transition and reprogramming

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20031049A2 (en) 2001-06-23 2004-06-30 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
EP1465900B1 (en) * 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
PT2476667E (pt) 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US7592352B2 (en) * 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP4242911B2 (ja) 2004-08-26 2009-03-25 ファイザー・インク プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
CA2577937C (en) 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1786777A1 (en) 2004-08-26 2007-05-23 Pfizer, Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
BRPI0608659A2 (pt) * 2005-04-06 2010-11-30 Astrazeneca Ab composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
AU2005335661A1 (en) * 2005-08-16 2007-02-22 F. Hoffmann-La Roche Ag Novel 4-amino-thieno[3,2-C]pyridine-7-carboxylic acid amides
AU2006284751A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2007056625A2 (en) * 2005-11-04 2007-05-18 Smithkline Beecham Corporation Thienopyridine b-raf kinase inhibitors
PT1963302E (pt) 2005-12-05 2013-04-09 Pfizer Prod Inc Polimorfos de um inibidor de c-met/hgfr
US7989461B2 (en) * 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
KR20090007347A (ko) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제
EP2038289A2 (en) * 2006-04-21 2009-03-25 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
EP2215085B1 (en) 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
UY31478A1 (es) 2007-11-21 2009-07-17 Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
KR101034351B1 (ko) 2008-05-14 2011-05-16 한국화학연구원 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물
WO2009140549A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
CN102007127A (zh) 2011-04-06
CA2711078A1 (en) 2009-08-13
EP2265616B1 (en) 2013-11-20
AU2009212338A1 (en) 2009-08-13
EP2265616B8 (en) 2014-01-08
CL2009000275A1 (es) 2009-06-12
EA201070929A1 (ru) 2011-04-29
UY31638A1 (es) 2009-09-30
US20090197864A1 (en) 2009-08-06
TW200944201A (en) 2009-11-01
JP2011511094A (ja) 2011-04-07
PE20091414A1 (es) 2009-09-23
ZA201005554B (en) 2011-04-28
US8022206B2 (en) 2011-09-20
KR20110014971A (ko) 2011-02-14
ES2451024T3 (es) 2014-03-26
EP2265616A1 (en) 2010-12-29
WO2009100282A1 (en) 2009-08-13
AR070317A1 (es) 2010-03-31
IL206758A0 (en) 2010-12-30
MX2010008638A (es) 2010-08-30

Similar Documents

Publication Publication Date Title
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
DOP2007000080A (es) Piridin [3,4-b] pirazinonas
BRPI0914657A2 (pt) piridin-2-onae piridazin-3-onas substituídas
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
NO2021006I1 (no) Quofenix, delafloksacin
BRPI1006113A2 (pt) "derivado de piridina".
BRPI0811718A2 (pt) Derivados de 3,3-espiroindolinona
BRPI0914533A2 (pt) "métodos"
EP2272042A4 (en) SMART CAR COMPLETION
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
BRPI0915064A2 (pt) derivados de qunoxalinadiona
ZA201005554B (en) Furo-and thieno[3,2-c]pyridines
UY33125A (es) Diaza-espiro-[5,5]-undecanos
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0906357A2 (pt) Derivados de oxazepinopirimidona arilamida substituídos
EP2257169A4 (en) TETRAHYDROTHIENPYRIDINE
BRPI0911625A2 (pt) Métodos
DE102008005493A8 (de) 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
BRPI0922652A2 (pt) Derivados de quinazolinamida
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI1008173A2 (pt) "derivados de piridina espiroindolinona"
BRPI0815059A2 (pt) Derivado de 1,3-di-hidroisoindol
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI0809678A2 (pt) Métodos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2367 DE 17-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.